MarginsXMarginsX
Home › Markets › Health Care › APMD

Apnimed Inc. (APMD)

APMD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$16.28
-3.78% on the day
Market cap
$677.7M
Small cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerAPMD on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2026
SEC CIK0001745648
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
not enough data
$172.8M cash at June 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed September 8, 2026
Insider net buying, 12 months
$5.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within the twelve months after the date that these consolidated financial statements are issued."
10-Q 2026-09-08
Cash and burn$172.8M cash.Report 2026-06-30
Shares outstanding41,630,779 (2026-09-04).Cover page 2026-09-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-07-29
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $5.2M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$12.1M$125.9MNot filed$172.8M$40.3MNeeds four quarters10-Q 2026-09-08
Q2 2026
2026-03-31
Not filed$67.7MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-09-08
Q2 2026
2025-06-30
$17.1M-$69.5MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-09-08
Q2 2026
2025-03-31
Not filed-$28.6MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-09-08

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42026-07-31
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-11-16

Source: SEC EDGAR submissions feed, 61 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+12.1%
1 month-5.1%
3 months-41.2%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-48.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ANNXAnnexon Inc.$3.57-8.93%$681.0M
JANXJanux Therapeutics Inc.$10.92-3.96%$668.1M
ALMSAlumis Inc.$5.14-8.21%$667.3M
NVCTNuvectis Pharma Inc.$19.11-5.58%$657.2M
KURAKura Oncology Inc.$7.09-8.75%$651.4M
BCAXBicara Therapeutics Inc.$9.75-2.69%$647.3M
ANLAdlai Nortye Group Ltd.$10.03-5.47%$645.9M
OLMAOlema Oncology Inc.$7.36-2.65%$644.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier